Biotech Startups

SubjectWell operates a patient network that links individuals to clinical trials and connects them with healthcare providers and pharmaceutical sponsors. The company serves patients, clinical research organizations, and pharmaceutical companies seeking to recruit and retain participants for medical studies.

7 investors

Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.

7 investors

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.

7 investors

Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.

7 investors

Synvivia develops chemical control technology over cell behavior to optimize the biomanufacturing of high-value biopharmaceutical products. It operates in the synthetic biology and drug discovery space.

7 investors

TargED is a biopharmaceutical company developing therapeutics for thrombotic disorders, spun out from University Medical Center Utrecht. The company focuses on bringing novel compounds from early-stage research to clinical development.

7 investors

Teiko provides CLIA-validated high-dimensional cytometry services—including spectral flow and mass cytometry panels, blood preservation kits, gating, and a data analysis dashboard—for immune cell profiling in clinical trials. It serves pharmaceutical and clinical research teams running global Phase I-IV trials across the US, EU, and Australia.

7 investors

Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases. The company focuses on non-viral delivery methods to enable potentially curative genetic therapies.

7 investors

EVERY® manufactures animal-free egg white proteins using precision fermentation technology for food and beverage manufacturers. The company produces functional protein ingredients that replicate the properties of natural eggs.

7 investors

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

7 investors

Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists. It also offers technical support centers and imaging data management platforms for core labs.

7 investors

Tierra Biosciences develops high-performance protein design technology, serving biotechnology and pharmaceutical industries.

7 investors

TileDB builds a database platform for organizing, cataloging, and analyzing large-scale data across organizations. The product serves science and data teams seeking to extract insights from complex, diverse datasets.

7 investors

Valion Bio (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod, a TLR5 agonist that activates the innate immune system, for Acute Radiation Syndrome and oncology supportive care such as chemotherapy- and radiation-induced neutropenia. It also owns Velocity Bioworks, a U.S.-based contract development and manufacturing organization (CDMO) in San Antonio, Texas.

7 investors

Transcend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications. The company is a clinical-stage biotech firm focused on neuroscience-based drug development.

7 investors

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.

7 investors

Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.

7 investors

Ultima Genomics develops genomic sequencing technology to scale omics information for advances in biology and human health improvements.

7 investors

Uncommon Therapeutics uses advanced technologies to develop drugs targeting rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental disorder affecting approximately 1 in 10,000 girls. The company combines disease expertise with efficient drug development to advance therapeutics from discovery to clinical application.

7 investors

Undermind provides AI-powered research discovery tools that help R&D teams find relevant scientific papers and research quickly. The platform serves biotech and pharmaceutical companies conducting drug discovery and development work.

7 investors

Unity Biotechnology was a biotechnology company that is no longer operating. The page provides only wind-down contact information and does not describe the company's products or focus.

7 investors

Using few-shot learning to design better drug candidates, faster

7 investors

Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields. It positions itself as a company focused on reshaping how new drugs are discovered.

7 investors

Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology. It serves healthcare providers using proprietary laboratory technology and AI/ML analytical tools for genomic testing and personalized medicine.

7 investors